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Abstract
Background: Inflammation in anterior uveitis is characterised by breakdown of the blood-ocular barrier, which
allows leakage of blood constituents of higher molecular weight into the aqueous humour. In routine clinical care,
increase in aqueous protein levels can be observed at the slit lamp as ‘flare’ and the severity can be graded using
various clinical grading systems, of which the Standardization of Uveitis Nomenclature (SUN) grading system is
most commonly used. Alternative instrument-based technologies are available, which can detect aqueous protein
levels in an objective and quantifiable way. This review will identify instruments capable of measuring anterior
chamber inflammation in this way, their level of reliability, and how well the measurements correlate with clinical
grading and/or actual aqueous protein concentration.
Methods: Standard systematic review methodology will be used to identify, select and extract data from studies
that report the use of any instrument-based technology in the assessment of aqueous protein levels. Searches will
be conducted through bibliographic databases (MEDLINE, EMBASE and Cochrane Library), clinical trial registries and
the grey literature. No restrictions will be placed on language or year of publication. The outcomes of interest are
the level of correlation between identified instrument-based test measurements, clinical grading and/or actual
aqueous protein concentration, as well as the reliability of each index test identified. Study quality assessment will
be based on QUADAS2. Correlation and reliability outcomes will be pooled and meta-analysed if appropriate.
Discussion: The assessment of inflammation in anterior chamber protein levels currently relies on crude and
subjective clinical examination. The findings of this review will identify non-invasive technologies which show good
correlation with actual protein concentration, which could be used in routine clinical practice for objective
monitoring of AC inflammation.
Systematic review registration: PROSPERO CRD42017084167. Study screening stage has just been completed.
Keywords: Systematic review, Uveitis, Anterior chamber flare, Intraocular inflammation, Aqueous humour, Proteins,
Blood-ocular barrier, Monitoring test, Diagnostic test, Optical coherence tomography, Laser flare photometry, Laser
flare meter, Tyndallometry
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Background
Uveitis, a significant cause of blindness worldwide
with a global prevalence of 38–114.5 per 100,000 [1,
2], describes a group of conditions characterised by
intraocular inflammation [3, 4]. Although uveitis can
occur at any age [3], it commonly affects the
working-age group and therefore has a substantial so-
cioeconomic impact [5].
Anterior uveitis is characterised by inflammation of
the anterior uveal tract. The acute symptoms are pri-
marily pain, redness and photophobia, but vision can
be affected. With adequate treatment, these symp-
toms are reversible; however, permanent and vision-
threatening complications (such as posterior syne-
chiae formation, cataract and secondary glaucoma)
can develop in the presence of prolonged inflamma-
tory activity.
Inflammation in the anterior chamber (AC) can
be observed as changes of the aqueous humour.
The aqueous humour is a clear fluid in the anterior
chamber of the eye that provides nutrition, removes
excretory products of metabolism, transports neuro-
transmitters, stabilises the ocular structure and con-
tributes to the regulation of the homeostasis of
ocular structures [6]. In health, the aqueous
humour is well isolated from the blood by blood-
aqueous barriers including the endothelial cells of
the iris capillaries and retinal vessels and non-
pigmented ciliary body epithelium. The aqueous is
mostly water, but also contains electrolytes, carbo-
hydrates, glutathione, urea, oxygen, carbon dioxide,
and proteins [6, 7]. In the absence of inflammation,
only small proteins are present in low concentra-
tions in the aqueous. Inflammation causes break-
down of the blood-aqueous barriers and results in
the release of inflammatory cells and proteins of
higher molecular weight into the eye [8, 9]. The ac-
cumulation of proteins in the aqueous humour can
be observed as flare or Tyndall effect, which is an
optical phenomenon of cloudiness in the aqueous
humour due to increased protein content.
The ability to accurately measure the concentration
of proteins in the aqueous is clinically important for
detecting acute inflammatory episodes and assessing
response to treatment [10]. There are several estab-
lished methods for quantifying aqueous protein
levels, including clinical examination and laser flare
photometry. However, with the exception of aqueous
paracentesis (invasive sampling of the aqueous
humour), existing methods are surrogate measures
relating to the change in optical properties of the
aqueous humour when protein levels are increased.
Each method has its limitations, and it is unclear
whether measurements from different methods agree
with each other. The following section discusses the
pros and cons of existing measures for aqueous pro-
tein concentration.
Invasive quantification of aqueous protein sampling:
aqueous paracentesis
Currently, the only means of directly measuring the
protein content of the aqueous is by aqueous para-
centesis and analysis in a laboratory setting [11, 12].
While this method provides the most accurate quanti-
fication of aqueous constituents, it is not used rou-
tinely in clinical practice as it is invasive and carries
risk of sight-threatening complications [13]. Conse-
quently, its use is mainly limited to the research set-
ting, and non-invasive methods are used preferably in
clinical practice.
Non-invasive quantification of aqueous protein level
Clinical examination
The current clinical standard for AC flare grading was
defined at the Standardisation of Uveitis Nomenclature
(SUN) working group consensus meeting in 2005 [4].
Prior to this, several systems existed for grading AC flare
[14–17]. Slit-lamp biomicroscopy enables a clinician to
grade increasing protein concentrations in the aqueous
humour due to back-scattering of light emitted from a
slit-lamp. The SUN system grades flare according to the
observer’s ability to visualise details of the iris and lens
behind the aqueous. Grades range from 0, which corre-
sponds to no visible flare, to 4+, which corresponds to
intense flare (Table 1).
Grading of flare based on clinical examination is
subjective and subject to high intra- and inter-
observer variability [18]. In addition, it is a non-
continuous scale, leading to large steps in disease ac-
tivity between categories. Detection and monitoring of
inflammatory changes in anterior uveitis is critically
important for clinical management, decision making
and clinical trials investigating therapeutic agents [19].
The need for a more robust and reproducible method
of measurement is well-recognised within the uveitis
community. Newer imaging techniques have become
available in recent years; therefore, it is timely to
Table 1 The Standardisation of Uveitis Nomenclature (SUN)
working group grading scheme for anterior chamber flare [4]
Grade Flare Description
0 None
1+ Faint Barely detectable
2+ Moderate Iris and lens details clear
3+ Marked Iris and lens details hazy
4+ Intense Fixed coagulated aqueous with considerable fibrin
Source: Ref [4]
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carry out a review of whether they can be purposed
for this unmet need and evaluate how they compare
to the current standard.
Laser flare and cell photometry
In 1988, Sawa et al. first described laser flare photom-
etry (LFP) as a new method to precisely determine
protein concentration in the aqueous humour [20].
LFP is a rapid and non-invasive technique which
quantifies AC flare by projecting a laser beam
through the anterior chamber and measuring the
amount of back-scattered light. Particles present in
the aqueous reflect photons of light, which are then
measured by an inbuilt photomultiplier. The intensity
of back-scattered light is proportional to the concen-
tration and size of proteins in the aqueous chamber.
Most models of LFP are capable of measuring flare,
but the technology can also be used to count AC
cells. However, assessment of AC cells using LFP is
less accurate as inflammatory cells cannot be differen-
tiated from other large particles such as pigment par-
ticles, debris or red blood cells [9].
Optical coherence tomography (OCT)
OCT is an imaging technique which has become
available more recently. It uses coherent light to cap-
ture high resolution 2- and 3-dimensional images of
structures within the eye. It is a fast and non-invasive
method of obtaining high precision images and mea-
surements of ocular structure [21]. Anterior segment
OCT (AS-OCT) can provide cross-sectional imaging
of the AC. Recently, OCT has demonstrated the abil-
ity to detect higher light reflectivity signals on AS-
OCT during active inflammation [21].
Aim
The primary aim of this review is to identify all avail-
able non-invasive, instrument-based techniques with
the potential to quantify protein levels in the aqueous
as a measure of AC inflammation. We will evaluate
the level of correlation of these measurements with
clinical grading using slit lamp examination and/or
actual aqueous protein concentration. Where re-
ported, we will also evaluate the level of reliability of
each test.
A secondary aim of the review is to evaluate the cor-
relation between clinical grading and protein concentra-
tion measured by laboratory analysis of aqueous
samples.
The following questions are proposed:
 Which index tests have the potential to quantify AC
inflammation in uveitis?
 What is the level of correlation between the
index test and clinical grading?
 What is the level of correlation between the
index test and aqueous protein concentration?
 What is the level of repeatability of each test?
 What is the level of correlation between clinical
grading using the slit lamp and aqueous protein
concentration?
Methods
Protocol
This protocol has been designed in accordance with the
guidelines of Preferred Reporting Items for Systematic
Review and Meta-Analysis Protocol (PRISMA-P) [22].
The systematic review will be reported in accordance to
the PRISMA guidelines [23].
Systematic review registration
This systematic review has been registered on PROS-
PERO (CRD42017084167) [24].
Searches
Databases
Our search strategy will include the following areas of
interest: anatomical location (‘anterior chamber’), the
pathological finding (‘flare’) and the disease context
(‘uveitis’). To achieve optimal sensitivity, no search
terms will be applied for the ‘technologies/tests’. For
bibliographic databases, free text and index terms will
be combined for each search element where possible.
A sample search strategy for MEDLINE is included in
the Appendix 1. We will search:
 Bibliographic databases of published studies.
 MEDLINE (Ovid), 1946 to present
 Embase (Ovid), 1947 to present
 Cochrane Central Register of Controlled Trials
(CENTRAL), database inception to present
 Centre for Reviews and Dissemination database
(Health Technology Assessments and the
Database of Abstracts and Reviews of Effects),
database inception to present
 Registers of clinical trials
 Clinicaltrials.gov. www.clinicaltrials.gov
 WHO International Clinical Trials Registry
Platform (ICTRP portal). www.who.int/ictrp.
 Abstract and conference proceedings
 British Library’s ZETOC.
 Conference proceedings Citation Index (Web of
Science).
 Dissertations, theses
 British library Ethos
 ProQuest. www.proquest.com
 Grey literature
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 OpenGrey. www.opengrey.eu
No restrictions will be placed on year or language of
publication. The literature search results will be entered
onto EndNote (Clarivate Analytics, Philadelphia, PA) to
facilitate removal of duplicates, study selection, record-
ing decisions and references. References to other works
will be considered for inclusion.
Selection criteria
Participants/population
Those with evidence of anterior chamber flare and/or
a diagnosis of uveitis, irrespective of active or inactive
inflammation, will be included. There will be no re-
strictions on age, gender, ethnicity, or underlying aeti-
ology or anatomical subtype. Studies with only
healthy participants and studies on animals will not
be included.
Index test
Any study reporting one or more non-invasive,
instrument-based technology with the potential for
quantifying AC flare or aqueous protein measurements
will be included. To address the secondary outcome
(clinical grading versus laboratory measurements of
aqueous proteins), any clinical grading system can be
considered the index test.
Reference test
The reference test should be either the current clinical
standard—clinician-based AC flare grading, or the la-
boratory standard—measurements of aqueous protein
from aqueous paracentesis.
For the clinical grading versus laboratory analysis, the
reference test must be a laboratory-based technique for
measuring aqueous protein concentration of extracted
aqueous samples.
Primary outcomes
The level of correlation (correlation coefficient) of
index test measurements with clinical grading using
slit lamp examination and/or actual aqueous protein
concentration.
Secondary outcome
Intra/inter-observer reliability and repeatability of an
index test (kappa statistic) and the level of correlation
between clinical grading and actual protein concentra-
tion (clinical grading as the index test and protein
concentration as the reference test).
Type of study
There will be no restrictions on study design; how-
ever, evaluation of correlation between index test
and clinical grading using slit-lamp examination/
aqueous protein measurements require both tests to
be done in a cross-sectional manner. If multiple
time points are included, we will include results
from all time points, but comparisons between tests
will be cross-sectionally. Only those studies where
measurements are taken within a reasonable time
point (within 24 h of each other) will be included.
Case reports involving only one subject, commen-
taries, opinion articles and pictorial articles will not
be included.
Selection process
Titles and abstracts of studies will be screened for rele-
vance to the review, to remove obviously irrelevant stud-
ies Two independent reviewers will carry out study
selection and reach consensus by discussion or referral
to a third reviewer.
Full text of potentially relevant articles will be re-
trieved and assessed for inclusion in the review against
the full selection criteria.
Data extraction
A standardised data extraction form in Microsoft Excel
(Microsoft, Washington, US) will be used to extract data
from included studies. The extraction process will be
carried out by two independent reviewers with referral
to a third reviewer if necessary. Information extracted
from all studies will include:
 Study characteristics
 Title, authors, publication year, journal and
language
 Sample size
 Study design
 Index test used
1. Manufacturer and model (including
resolution, default settings)
2. Measurements acquisition protocol
3. Measurement analysis protocol
 Clinical grading system measurements
1. Clinical grading system used and whether any
modifications were made
2. Number of observers
 Aqueous protein concentration
1. Context and reason for aqueous extraction
2. Aqueous extraction protocol
3. Aqueous analysis protocol
 Patients’ characteristics
 Age, gender and ethnicity
 Underlying aetiologies (anatomical subtype,
aetiological classification)
 Active or inactive disease
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 If the study involves a therapeutic intervention:
treatment details (indication, drug, dosage, route,
subject pre/post treatment status, length of
follow-up and number of time points suitable for
review question)
 Outcomes and findings
 Data will be extracted in preparation for four
separate analyses:
1. Evaluation of correlation between index tests
and actual aqueous protein concentration:
The correlation coefficient will be directly
extracted.
2. Evaluation of correlation between index
tests and clinical grading systems: The
correlation coefficient reported will be
directly extracted.
3. Evaluation of correlation between the clinical
grading system and aqueous protein
concentration: The correlation coefficient will
be directly extracted.
If no correlation coefficient is reported, Index
and reference test measurements will be
extracted and, provided they are matched, used
to calculate the correlation coefficient. If the
two measurements are not matched, we will
contact the authors for matched
measurements.
4. Evaluation of reliability and repeatability of an
index test: Studies reporting intra- and inter-
observer reliability will be analysed separately
for assessment of repeatability. The reported
kappa values will be extracted for intra-
observer reliability, inter-observer reliability
or both.
Cross-sectional measurements may be nested within
longitudinal studies whose aims are not primarily to
compare performance or correlation between two tests.
In this situation, measurements at each time point will
be extracted and analysed as individual cross-sectional
comparisons.
Quality assessment
All included studies will be assessed for quality
using elements of the Quality Assessment of Diag-
nostic Accuracy Studies tool (QUADAS2) [25]. Al-
though QUADAS2 is designed for comparison of
diagnostic accuracy, rather than agreement of test
measurements, it is the most suitable existing tool
for evaluating risk of bias in diagnostic tests. We
have modified elements of the existing QUADAS2
signalling questions to suit the aims of this system-
atic review (see Appendix 2). For example, the ori-
ginal QUADAS2 framework includes a question
regarding whether thresholds were used and pre-
specified. We have removed this item as we are not
aiming to assess diagnostic accuracy. Similarly, we
have supported the QUADAS2 with additional items
such as the addition of the question ‘were index test
acquisition and analysis parameters determined a
priori and consistent for all study participants?’
Existing questions regarding blinding during test in-
terpretation, applicability to the review question,
and flow and timing of tests are kept as they remain
important for this review.
Assessment will be carried out at the study level.
Two independent reviewers will carry out quality as-
sessment and refer to a third reviewer if needed. For
studies assessing correlation between two tests, the
four risks of bias domains below will be rated as low,
high or unclear.
For studies investigating the reliability of a single index
test, additional considerations will be made for:
1. Intra-observer reliability studies: the conditions
under which the index test was performed should
be reported and standardised.
2. Inter-observer reliability studies: any differences
between observer characteristics, such as seniority
and experience, should be reported.
Data synthesis
Studies will be included in four groups for data syn-
thesis, one for each outcome: correlation between
index test and the clinical grading, correlation be-
tween index test and aqueous protein concentration,
correlation between the SUN grading system and la-
boratory measurement of aqueous protein concentra-
tion, and reliability of index test.
For each outcome, a narrative synthesis of tabulated
evidence will be conducted and, where possible, sup-
ported with a meta-analysis.
1. Evaluation of correlation between index test and the
SUN grading system
These studies will be grouped by the type of
technology used for the index test (i.e. LFP, OCT).
If the data permits, correlation coefficients between
each index test versus clinical grade will be
compared and pooled for meta-analysis using a ran-
dom effects model.
2. Evaluation of correlation between index test and
laboratory measurement of aqueous protein
concentration
3. Evaluation of correlation between the SUN grading
system and laboratory measurement of aqueous
protein concentration
4. Evaluation of reliability of an index test
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These studies will be grouped by type of technology
as above. We will analyse intra- and inter-observer
reliability separately for each technology. If the data
permits, reliability values (such as kappa values) will
be compared and pooled for meta-analysis.
Studies will be assessed for clinical and methodo-
logical homogeneity to determine whether it is pos-
sible appropriately pool data for meta-analysis. The
I2 statistic will be used to quantify heterogeneity
across studies in each meta-analysis. Correlation co-
efficients will be normalised using Fisher’s Z trans-
formation for meta-analysis and back transformed
for inference. Meta-analysis of kappa statistics will
be performed using an inverse-variance weighted
random effects model with standard errors esti-
mated from reported 95% confidence intervals. All
data will be reported narratively, regardless of
whether data pooling and meta-analysis are possible
or not.
Depending on the study data, appropriate sensitivity
analyses will be carried out if there is significant het-
erogeneity between studies. Subgroup analyses for
anatomical and aetiological subtypes of uveitis, index
test technology and experience of graders (for clinical
AC flare grading) will be considered to explore
sources of heterogeneity. It is expected that only a
small number of studies will meet inclusion criteria,
which will limit our capacity to carry out meaningful
subgroup analyses.
Discussion and potential impact
The assessment of inflammation in anterior uveitis cur-
rently relies on imperfect clinical methods. An increase
in aqueous protein concentration is a detectable change
which occurs in the presence of inflammatory break-
down of the blood ocular barrier. Laboratory measure-
ment of aqueous protein concentration in aqueous
samples obtained through paracentesis is a good gold
standard test but carries too many risks to make it prac-
tical for monitoring patients. Thus, clinicians must re-
sort to surrogate markers for aqueous protein levels
such as ‘flare’.
Whilst the SUN grading system marked a significant
effort towards unifying the method for assessing uveitic
inflammation, it continues to rely on clinical examin-
ation and the subjective appearance of aqueous ‘clarity’.
Many factors can also affect an observer’s ability to ob-
serve flare including the slit-lamp optics, degree of illu-
mination, ambient conditions and the observer’s level of
expertise [26].
The potential for instrument-based techniques for
assessing AC inflammation carries significant ad-
vantages over clinical grading systems because they
are objective, less operator dependent and produce
a continuous numerical value that is precise at even
low levels of inflammation. Objective measures of
inflammation for monitoring AC cells and vitreous
haze have been proposed, and OCT measurement
of central macular thickness is already established
in routine clinical practice [19, 21, 27, 28]. With
the use of automated analysis software, these tech-
niques could allow comprehensive objective disease
monitoring, potentially even in a virtual care
model.
To date, the use of non-invasive instrument-based
techniques for assessing AC flare has not been assessed
in a systematic way. The need for more objective mea-
sures of disease activity is well-recognised within the
uveitis community, and given the rise in new imaging
technologies over recent years which have the potential
to meet this demand, it is timely to carry out a review of
how they compare to the current standard. This system-
atic review will identify all technologies available for
quantifying ‘flare’ and their level of reliability and correl-
ation with laboratory measurement of aqueous protein
concentration and/or clinical grading. The findings of
this review could contribute to the validation process of
instrument-based methods for monitoring inflammatory
activity and guiding treatment decisions in uveitis.
Appendix 1
Table 2 MEDLINE search strategy
Number Search
1 Anterior Chamber. Ti,ab.
2 Aqueous. Ti,ab.
3 Anterior segment. Ti,ab.
4 1 or 2 or 3
5 Flare*. Ti,ab,
6 Photon. Ti,ab.
7 Photons. Ti,ab.
8 Protein. Ti,ab.
9 Proteins. Ti,ab.
10 Photometry. Ti,ab.
11 Fluorophotometry. Ti,ab.
12 Tyndal* Ti,ab.
13 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14 Exp Uveitis/
15 Uveiti*. Ti,ab.
16 Inflamm*. Ti,ab.
17 Blood aqueous barrier. Ti,ab.
18 14 or 15 or 16 or 17
19 4 and 13 and 18
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Appendix 2
Table 3 Modified elements of the QUADAS2 signalling questions used for quality assessment
Domain Patient selection Index test* Reference standard Flow and timing
Description Describe methods of patient
selection: Describe included patients
(prior testing, presentation, intended
use of index test and setting):
Describe the index test
and how it was conducted
and interpreted:
Describe the reference
standard and how it was
conducted and interpreted:
Describe any patients who did not
receive the index test(s) and/or
reference standard or who were
excluded from the 2x2 table
(refer to flow diagram): Describe
the time interval and any
interventions between index
test(s) and reference standard:
Signalling
questions
(yes/no/unclear)
Was a consecutive or random
sample of patients enrolled?
Were the index test results
interpreted without
knowledge of the results
of the reference standard?
Is the reference standard
likely to correctly classify
the target condition?
Was there an appropriate interval
between index test(s) and
reference standard?
Was a case-control design avoided? Were index test acquisition
and analysis parameters
determined a priori and
consistent for all study
participants?
Were the reference standard
results interpreted without
knowledge of the results of
the index test?
Did all patients receive a reference
standard?
Did the study avoid inappropriate
exclusions?
i.e. Participants may be excluded if
justified in terms of interference
with index test measurement
(corneal opacities preventing
visualisation of anterior structures).
Did all patients receive the same
reference standard?
i.e. Was the reference test
conducted in the same way
for each patient?
For slit lamp examination: observer,
slit lamp settings
For laboratory protein measurements:
method of aqueous extraction,
sample storage and analysis.
Were all patients included in the
analysis?
Risk of bias:
High/low/
unclear
Could the selection of patients
have introduced bias?
Could the conduct or
interpretation of the index
test have introduced bias?
Could the reference standard,
its conduct, or its
interpretation have
introduced bias?
Could the patient flow have
introduced bias?
Concerns
regarding
applicability:
High/low/
unclear
Are there concerns that the
included patients do not
match the review question?
Are there concerns that
the index test, its conduct,
or interpretation differ
from the review question?
Are there concerns that the
target condition as defined
by the reference standard
does not match the review
question?
Italics denote signalling questions added by the authors for this systematic review.
*In index test, the signalling question regarding whether thresholds were used and pre-specified is not applicable for this review and was therefore removed
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